<PAGE>   1
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB


(Mark One)

[X]      QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
         ACT OF 1934


                  For the quarterly period ended June 30, 1999

[ ]      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934




                         Commission File Number: 0-18399


                         FOUNTAIN PHARMACEUTICALS, INC.
             (Exact name of registrant as specified in its charter)


Delaware                                              62-1386759
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)


                   7279 Bryan Dairy Road, Largo, Florida 33777
                    (Address of Principal Executive Offices)


                                 (727) 548-0900
              (Registrant's telephone number, including area code)


         Check whether the Registrant (1) filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the Registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days.

                            (1)     Yes   X                    No
                                        -----                     -----

                            (2)     Yes   X                    No
                                        -----                     -----
<PAGE>   2
                       APPLICABLE ONLY TO ISSUERS INVOLVED
           IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

         Check whether the Registrant filed all documents and reports required
to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934
after the distribution of securities under a plan confirmed by court.

                              Yes     X                    No
                                    ----                        ----


                      APPLICABLE ONLY TO CORPORATE ISSUERS:

         State the number of shares outstanding of each of the Registrant's
classes of Common Stock, as of August 10, 1999:

Common Stock, par value             $.001 - 2,375,796

Class B Common Stock, par value     $.001 - 4,505


                 Transitional Small Business Disclosure Format:

                              Yes                          No    X
                                    ----                        ----

                                        2
<PAGE>   3
                         FOUNTAIN PHARMACEUTICALS, INC.

                                      INDEX

<TABLE>
<CAPTION>
                                                                                                          Page
Part I.                Financial Information*

<S>                    <C>                                                                                <C>
    Item 1.            Condensed Financial Statements (Unaudited)

                       Balance Sheets - September 30, 1998,                                                   4
                       and June 30, 1999 (Unaudited)

                       Statements of Operations - for the three and                                           5
                       nine months ended June 30, 1999, and 1998
                       (Unaudited)

                       Statement of Stockholders' Equity -                                                    6
                       for the period from September 30, 1998
                       through June 30, 1999 (Unaudited)

                       Statements of Cash Flows - for the nine                                                7
                       months ended June 30, 1999 and 1998
                       (Unaudited)

                       Notes to Condensed Financial Statements                                                8
                       (Unaudited)

    Item 2.            Management's Discussion and                                                            9
                       Analysis or Plan of Operation

Part II.               Other Information

    Item 1.            Legal Proceedings                                                                     12
    Item 2.            Changes in Securities                                                                 12
    Item 3.            Defaults Upon Senior Securities                                                       12
    Item 4.            Submission of Matters to a Vote                                                       12
                       of Security Holders
    Item 5.            Other Information                                                                     12
    Item 6.            Exhibits and Reports on Form 8-K                                                      13
</TABLE>

* The accompanying financial information is not covered by an Independent
  Certified Public Accountant's Report.

                                        3
<PAGE>   4
                         FOUNTAIN PHARMACEUTICALS, INC.
                                 BALANCE SHEETS

                      ASSETS

<TABLE>
<CAPTION>
                                             June 30, 1999       September 30,
                                              (Unaudited)            1998
                                              -----------            ----
   (Unaudited)
Current assets:
<S>                                           <C>               <C>
Cash and cash equivalents                     $  200,506        $  452,099
Accounts receivable, net of allowance            274,966           205,194
  for uncollectible accounts
   ($13,266, June 30, 1999;
   $16,000, September 30, 1998)
Inventories                                      307,488           195,240
Prepaid expenses                                 149,539            32,723
                                              ----------        ----------
Total current assets                             932,499           885,256

Furniture and equipment, less
    accumulated depreciation
    ($287,990, June 30, 1999;
    $268,374, September 30, 1998)                130,554           101,343

Patent costs, less accumulated
    amortization ($33,496 June 30,
    1999; $26,705, September 30, 1998)           145,277           139,525


Other assets                                       9,646             6,595
                                                --------          --------



Total assets                                  $1,217,976        $1,132,719
                                              ==========        ==========
</TABLE>

                      LIABILITIES AND STOCKHOLDERS' EQUITY

<TABLE>
<CAPTION>
                                                                   June 30, 1999       September 30,
                                                                    (Unaudited)           1998
                                                                    -----------           ----
        Current liabilities:
<S>                                                                <C>                <C>
            Current  portion  of notes payable, bank               $    15,660        $    14,497
            Current  portion  of liabilities
               not subject to compromise                                                    2,584
            Notes payable, Director                                  1,123,309
            Accounts payable and accrued expenses                      183,632            222,971
                                                                   -----------        -----------


            Total current liabilities                                1,322,601            240,052
                                                                   -----------        -----------


        Notes payable, bank                                             35,782             47,677
                                                                   -----------        -----------
        Stockholders' equity
            Preferred stock, par value $.001,
               2,000,000 shares authorized, issued
               and outstanding (1.2 votes per share)                     2,000              2,000

            Common stock, par value $.001, 50,000,000
               shares authorized; 2,375,796, June 30, 1999;
               2,375,796, September 30, 1998, issued
               (1 vote per share)                                        2,376              2,376
            Class B common stock; par value $.001,
               5,000,000 shares authorized; 4,505, June
               30, 1999; 4,505, September 30, 1998, shares
               issued  and outstanding (5 votes per share)                   5                  5
            Additional paid-in capital                              17,056,450         17,056,449
            Accumulated deficit                                   (17,201,214)        (16,215,816)
                                                                   -----------        -----------

               Subtotal stockholders' equity (Deficit)               (140,383)            845,014

            Less: Treasury Stock                                          (24)                (24)
                                                                   -----------        -----------

               Total stockholders' equity (Deficit)                  (140,407)            844,990
                                                                   -----------        -----------

        Total liabilities  and stockholders' equity                $ 1,217,976        $ 1,132,719
                                                                   ===========        ===========
</TABLE>

                  See notes to condensed financial statements.


                                       4
<PAGE>   5
                         FOUNTAIN PHARMACEUTICALS, INC.
                            STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                      Three Months Ended                  Nine Months Ended
                                                            June 30,                            June 30,
                                                            --------                            --------
                                                     1999             1998               1999                 1998
                                                     ----             ----               ----                 ----
<S>                                        <C>                 <C>                  <C>                 <C>
Revenue                                      $   933,833         $   909,329          $ 1,771,157         $ 1,237,862

Cost of sales                                    503,245             483,580              977,032             653,139
                                             -----------         -----------          -----------         -----------

Gross profit                                     430,588             425,749              794,125             584,723
                                             -----------         -----------          -----------         -----------
Operating expenses:
    Research and development                      90,567             119,929              321,110             281,792
    General and administrative                   206,671             114,779              803,358             367,277
    Selling                                      349,157             432,503              848,046             836,528
    Depreciation and amortization                  9,601               5,497               26,656              15,292
                                             -----------         -----------          -----------         -----------

Total operating expenses                         655,996             672,708            1,999,170           1,500,889
                                             -----------         -----------          -----------         -----------

Loss from operations                            (225,408)          (246,959)          (1,205,045)            (916,166)

Other income (expenses):
    Interest income                                1,288              19,141                6,564             75,567
    Interest expense                             (19,099)             (1,722)             (34,707)            (8,127)
    Litigation settlement                                                                 250,000
    Other income (expense)                        (3,669)             (3,777)              (2,209)            (4,925)
                                            ------------         -----------          -----------        -----------

Total other income (expenses)                    (21,480)             13,642              219,648             62,515
                                            ------------         -----------          -----------        ------------

Net loss                                       ($246,888)          ($233,317)           ($985,397)          ($853,651)
                                            ============         ===========          ===========        ============



Earnings per share:


    Net loss per share                             ($.11)              ($.10)              ($.42)             ($.36)
                                             ===========         ===========         ===========        ===========

    Weighted average number of shares
    outstanding:                               2,380,301           2,380,301           2,380,301           2,380,301
                                             ===========         ===========         ===========        ============
</TABLE>



                  See notes to condensed financial statements.


                                        5
<PAGE>   6
                         FOUNTAIN PHARMACEUTICALS, INC.
                  STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
          FOR THE PERIOD FROM SEPTEMBER 30, 1998 THROUGH JUNE 30, 1999
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                                    Class B
                                       Common Stock              Common Stock                   Preferred Stock
                                   Shares        Amount       Shares      Amount            Shares            Amount
                                   ------        ------       ------      ------            ------            ------
Balances

<S>                           <C>             <C>           <C>        <C>             <C>            <C>
    October 1, 1998             2,375,796       $ 2,376       4,505      $     5         2,000,000      $      2,000



Net Loss for the Period
                                ---------       -------       -----      -------         ---------      ------------

Balances,
    June 30, 1999               2,375,796       $ 2,376       4,505           $5         2,000,000      $      2,000
                                =========       =======      ======      =======         =========      ============
</TABLE>







<TABLE>
<CAPTION>
                            Additional        Accumulated           Treasury Stock
                         Paid-in  Capital       Deficit         Shares          Amount          Total
                         ----------------       -------         ------          ------          -----


 <S>                     <C>                 <C>               <C>             <C>         <C>
Balances


    October 1, 1998         $ 17,056,450      ($16,215,817)       12             ($24)      $    844,990



Net Loss for the Period                           (985,397)                                     (985,397)
                            ------------      ------------        --             ----       ------------

Balances,
    June 30, 1999           $ 17,056,450       ($17,201,214)      12             ($24)       ($   140,407)
                            ============      =============      =======          ====       ============
</TABLE>




                  See notes to condensed financial statements.






                                        6
<PAGE>   7
                         FOUNTAIN PHARMACEUTICALS, INC.
                            STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                                                    Nine Months Ended June 30,
                                                                                    --------------------------
                                                                                1999                       1998
                                                                                ----                       ----
Cash flows from operating activities:
<S>                                                                      <C>                         <C>
    Net loss                                                             ($   985,397)               ($   853,651)
    Adjustments to reconcile net loss to
        net cash used in operating activities:
        Depreciation                                                           19,865                      10,298
        Amortization                                                            6,791                       4,994

        Loss on disposal of assets                                              1,988
        Increase (decrease) in cash due to changes in:
           Accounts receivable                                           (     69,772)                (   300,799)

           Inventories                                                   (    112,248)                (   146,696)

           Prepaid expenses and other assets                             (    116,816)                (    57,018)

           Other assets                                                  (      3,051)
           Accounts payable and accrued expenses                         (     39,339)                    287,594
                                                                          -----------                 -----------


Net cash used in operating activities                                     ( 1,297,979)                ( 1,055,278)
                                                                          -----------                 -----------

Cash flows from investing activities:
    Deferred patent costs incurred                                        (    12,543)                (     1,408)

    Acquisition of furniture and equipment                                (    51,064)                (    80,054)
                                                                          -----------                 -----------


Net cash used in investing activities                                     (    63,607)                (    81,462)
                                                                          -----------                 -----------



Cash flows from financing activities:
    Proceeds from line of credit                                             100,000
    Repayment of line of credit                                           (  100,000)
    Director loans                                                         1,123,309
    Repayment of liabilities under Reorganization Plan                    (    2,584)                 (    90,201)
    Proceeds from equipment financing                                                                      66,110
    Payments on note payable, bank                                        (   10,732)                 (       538)
    Repayment of officer loan                                                                         (    40,000)
    Repurchase of factional shares                                                                    (        24)
                                                                          ----------                  -----------



Net cash provided by (used in) financing activities                        1,109,993                  (    64,653)
                                                                          ----------                  -----------


Decrease in cash and cash equivalents                                    (   251,593)                 ( 1,201,393)

Cash and cash equivalents at beginning of period                             452,099                    2,371,071
                                                                          ----------                  -----------


Cash and cash equivalents at end of period                               $    200,506                $  1,169,678
                                                                        =============                ============
</TABLE>



                 SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION

Interest paid was $ 6,435 and $8,127 for the nine months ended June 30, 1999 and
                              1998, respectively.


                  See notes to condensed financial statements.

                                        7
<PAGE>   8
                         FOUNTAIN PHARMACEUTICALS, INC.
                     NOTES TO CONDENSED FINANCIAL STATEMENTS
                FOR THE NINE MONTHS ENDED JUNE 30, 1999 AND 1998
                                   (UNAUDITED)


1.       The financial statements and notes thereto should be read in
         conjunction with the financial statements and notes for the year ended
         September 30, 1998.

2.       In the opinion of management, all adjustments (consisting only of
         normal recurring accruals) necessary for a fair presentation of the
         results of operations for the periods presented have been included. The
         results of operations for the nine months ended June 30, 1999 and 1998
         are not necessarily indicative of the results for a full year.



































                                        8
<PAGE>   9
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

         BACKGROUND

                  The Company was organized during 1989 to develop and
commercialize certain proprietary compound encapsulation technologies. Following
several years of continued developmental efforts, the Company was able to secure
patents on several aspects of its technologies in the United States and Europe,
introduce branded products in certain markets and develop strategic associations
with pharmaceutical companies.

         From inception through 1994, the Company remained in the development
stage while experiencing substantial losses. Its principal source of capital was
derived from a series of private financing transactions and an initial public
offering in 1990. Sales revenues during this period were insufficient to offset
the Company's operating costs and liabilities. Consequently, the Company filed
for protection under Chapter 11 of the United States Bankruptcy Code in the
United States Bankruptcy Court for the Middle District of Florida, Tampa
Division on November 30, 1994. Upon successfully reorganizing its operations and
finances, the Company emerged from bankruptcy in July 1996.

         In July 1997, the Company completed a private placement of 2,000,000
newly-designated and issued shares of Series A Convertible Preferred Stock (the
"Preferred Stock") to Fountain Holdings, LLC ("Holdings"), a Wyoming limited
liability company, controlled by Joseph S. Schuchert, Jr. As a result of this
private placement (the "Private Placement"), the Company obtained additional
working capital of $2.5 million, which it utilized to enhance the expansion of
the Company's sales and marketing program, as well as to further the Company's
research and development efforts. As a result of significant increases in
marketing costs associated with the expansion of existing product lines and the
introduction of new products during fiscal 1998, which were not offset by sales
revenues during the period, the Company substantially utilized its working
capital resources. Accordingly, the Company initiated a program to obtain
additional working capital. In order to provide working capital in the near
term, as of December 31, 1998, the Company entered into a secured credit
arrangement with Mr. Schuchert, a Director of the Company. The credit agreement
provides for a two year line of credit of up to $1,500,000 subject to the
Company satisfying certain agreed upon quarterly operating budget guidelines. In
order to fund operations in the long term and pursue its business strategy, the
Company intends to continue to seek additional sources of capital, including
debt and equity financing. However, there can be no assurances that such
financing will be available or, that it will be available upon terms
advantageous to the Company. See "LIQUIDITY AND CAPITAL RESOURCES."

         RESULTS OF OPERATIONS

         During the quarter ended June 30, 1999, the Company realized a net loss
of $246,888 on revenues of $933,833, compared to net loss of $233,317 on
revenues of $909,329 for the quarter ended June 30, 1998. The increase in losses
from the prior year's quarter ended June 30, 1998, is attributable primarily due
to increased sales and marketing efforts relating to existing and new markets
and interest expense on a secured line of credit arrangement with Mr. Joseph S.
Schuchert, Jr. (See "LIQUIDITY AND CAPITAL RESOURCES.") The increase in revenues
of 2.7% from the prior year's quarter



                                       9
<PAGE>   10
ended June 30, 1998 was a result of earlier than expected re-orders and
increased sales growth from the Company's European licensees which occurred in
the quarter ended June 30, 1999. The Company expects additional orders from
these licensees during subsequent months of the fiscal year ending September 30,
1999. However, there can be no assurances that subsequent orders will be
received.

         During the quarter ended June 30, 1999 the Company incurred operating
expenses of $655,996, a 2.5% decrease over operating expenses of $672,708 in the
quarter ended June 30, 1998. This decrease in expenses was primarily due to the
timing of research and development clinical research studies, relating to new
projects and formulations, that are expected to be completed during the fourth
fiscal quarter ending September 30, 1999.

         During the nine months ended June 30, 1999, the Company incurred a net
loss of $985,397 on revenues of $1,771,157, compared to a net loss of $853,651
on revenues of $1,237,862 for the comparable period ended June 30, 1998. This
increase in losses from the prior year's nine months ended June 30, 1998, is
attributable primarily to expenses relating to increased sales and marketing
efforts, legal fees relating to the Dermik Laboratories, Inc. lawsuit and
clinical research studies. The increase in revenues from the prior year's nine
months ended June 30, 1998, was a result of increase in orders from the
Company's European licensees of sunscreen product for the current summer season
as well as proceeds from the settlement relating to the Dermik Laboratories,
Inc. lawsuit.

         LIQUIDITY AND CAPITAL RESOURCES

         From inception through the quarter ended June 30, 1994, the Company's
principal sources of working capital were derived from a series of private
financing transactions and an initial public offering in 1990. As a result of
the Company's declining equity and assets, the Company's securities were
delisted from The NASDAQ SmallCap Market(SM) during May 1994 and the securities
have since traded on the less liquid market of the OTC Bulletin Board.

         During the period from the quarter ended June 30, 1994 throughout the
bankruptcy proceedings, the Company's operations were funded primarily through
sales of products and from royalties, as well as the sale of 25,000,000 shares
(pre-split) of the Company's Common Stock to its then Chief Executive Officer at
a purchase price of $250,000 in December 1995. Since emerging from bankruptcy,
the Company's primary source of working capital have been sales revenues, short
term advances from the Company's then Chief Executive Officer and proceeds of
$2.5 million generated from a private placement offering in July 1997.

          As a result of such significant increase in marketing costs and legal
fees, which were not offset by sales revenues, the Company had substantially
utilized its working capital resources by December 1998. Accordingly, the
Company initiated a program to obtain additional working capital. In order to
provide working capital in the near term, as of December 31, 1998, the Company
entered into a secured credit arrangement with Mr. Schuchert. The Credit
Agreement provides for a secured line of credit of up to $1,500,000, the
principal and unpaid interest of which is due on the earlier of December 31,
2000, 180 days from written demand of Mr. Schuchert as lender or upon an event
of default under the agreement. The line of credit bears interest at an
adjustable monthly rate equal to the greater of (i) the prime rate quoted in the
Wall Street Journal,


                                       10
<PAGE>   11
plus 1-1/2% or (ii) 9%, which is payable monthly or may be accrued. The facility
is secured by all of the assets of the Company (subject to any existing liens).
The facility is subject to the Company satisfying certain agreed upon quarterly
operating budget guidelines. As of August 10, 1999, the Company had $1,173,309
outstanding under this facility plus accrued interest of $37,576 as of July 31,
1999. The proceeds of the loan have been utilized to fund operations and to pay
legal fees in connection with the Dermik lawsuit. Under the terms of the warrant
granted in connection with the Credit Agreement, Mr. Schuchert is entitled to
purchase 1.6 shares of Common Stock for each dollar advanced under the facility
and 1.6 shares of Common Stock for each dollar of accrued interest that is
unpaid when due under the facility at an exercise price of $.65 per share with
an expiration date of December 31, 2003. As of August 10, 1999, Mr. Schuchert is
entitled to purchase an aggregate of 1,937,416 shares of Common Stock under such
warrant.

          As of June 30, 1999, the Company had a deficit working capital of
$390,102, a decrease of $1,035,306 from the level of working capital of $645,204
as of September 30, 1998, and a $1,841,863 decrease from the Company's working
capital of $1,451,761 as of June 30, 1998. Such decrease in working capital is
primarily attributable to increased expenses associated with sales and marketing
efforts relating to existing and new markets, research and development relating
to new projects and formulations, legal fees relating to Dermik Laboratories,
Inc. lawsuit and additional personnel.

          The Company's sales revenues during the nine months ended June 30,
1999 were not adequate to offset expenses. Based upon the Company's current
budget guidelines as agreed to with Mr. Schuchert as lender, management believes
that the funds available under the line of credit will be sufficient to enable
the Company to meet its anticipated operating expenses through December 31,
1999. However, in order to continue longer term operations and to pursue its
business strategy, the Company will require additional financing unless and
until sales revenues provide sufficient working capital. The Company is in the
process of pursuing such additional sources of financing. There can be no
assurances that such financing will be available or that it will be available
upon terms advantageous to the Company. Failure to obtain such additional
financing or the earlier termination of the line of credit would have a material
adverse effect on the Company's ability to operate beyond December 1999.

         During the nine months ended June 30, 1999, the Company's other
principal sources of working capital were derived from revenues, royalties, the
litigation settlement with Dermik Laboratories, Inc., and a $100,000 line of
credit from First Union National Bank of Florida ("First Union"). The line of
credit bears interest at a rate of prime plus .5%, payable upon demand. As of
June 30, 1999 the Company had no outstanding balance due under its line of
credit of $100,000.

         EFFECTS OF INFLATION

         The Company does not expect inflation to materially effect its results
of operations, however, it does expect that its operating costs and the cost of
capital equipment to be acquired in the future may be subject to general
economic and inflationary pressures.



                                       11
<PAGE>   12
PART II. OTHER INFORMATION

ITEM 1.           LEGAL PROCEEDINGS

         None.

ITEM 2.           CHANGES IN SECURITIES

         None.


ITEM 3.           DEFAULTS UPON SENIOR SECURITIES

         None.

ITEM 4.           SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         On July 1, 1999, the Company filed an Information Statement in order to
ensure that the stock options granted under the 1998 Stock Option Plan qualify
as incentive stock options under Section 422 of the Internal Revenue Code of
1986, as amended and to comply with other tax provisions relevant to such
options. The 1998 Plan was approved by written consent of the holder of
1,251,100 shares (52.2%) of the outstanding Common Stock and the holder of all
of the Preferred Stock as of the Record Date, as permitted under Section 228 of
the Delaware General Corporation Law. The approval of the plan by the
stockholders of the company became effective July 21, 1999.

ITEM 5.           OTHER INFORMATION

         a.       General

         PRIVATE SECURITIES LITIGATION REFORM ACT SAFE HARBOR STATEMENT

         When used in this Quarterly Report on Form 10-QSB, the words "may",
"will", "expect", "anticipate", "continue", "estimate", "intend", and similar
expressions are intended to identify forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 regarding events, conditions and financial
trends which may affect the Company's future plans of operations, business
strategy, operating results and financial position. Such statements are not
guarantees of future performance and are subject to risks and uncertainties and
actual results may differ from those included within the forward-looking
statements as a result of various factors. Such factors include, among others:
(i) the Company's ability to obtain additional sources of capital to fund
operations in the long term and pursue its business strategies; (ii) the
Company's ability to retain existing or obtain additional licensees who act as
distributors of its products; (iii) the Company's ability to obtain additional
patent protection for its encapsulation technology; and (iv) other economic,
competitive and governmental factors affecting the Company's operations, market,
products and services. Additional factors are described in the Company's other
public reports and filings with the Securities and Exchange Commission. Readers
are cautioned not to


                                       12
<PAGE>   13
place undue reliance on these forward-looking statements, which speak only as of
the date made. The Company undertakes no obligation to publicly release the
result of any revision of these forward-looking statements to reflect events or
circumstances after the date they are made or to reflect the occurrence of
unanticipated events.



ITEM 6.             EXHIBITS AND REPORTS ON FORM 8-K

         (a)      Exhibits:

                  Exhibit 10.10 - 1998 Stock Option Plan

                  Exhibit 27 - Financial Data Schedule (Electronic filing only).

         (b)      Reports on Form 8-K:

                  None.



                                       13
<PAGE>   14
                         FOUNTAIN PHARMACEUTICALS, INC.

                                   SIGNATURES


         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                          FOUNTAIN PHARMACEUTICALS, INC.



Dated:  August 13, 1999                   /s/Gerald T. Simmons
                                          --------------------
                                          GERALD T. SIMMONS
                                          Chief Executive Officer, President and
                                          Chief Accounting Officer